London, UK - 10th April 2002 -- Results of a study published today in The Lancet suggest that ReminylTM (galantamine), the newest approved treatment for mild to moderate Alzheimer's disease, also is effective in treating a broad range of dementia symptoms in individuals with cerebrovascular disease (CVD). It is estimated that in one out of every four individuals with dementia, CVD is a primary cause or contributing factor (Neurology in Clinical Practice, 3rd edition, Bradley WG, Daroff RB, et al ed, page 1721).

Reminyl is the first Alzheimer's medication for which data in this population have been presented, and now published in a peer-reviewed medical journal. The study results indicate that Reminyl can benefit these patients' cognition (memory, language and reasoning skills), ability to function (perform activities of daily living) and behavior (less anxiety, delusions and agitation).

The new data are being submitted to health authorities worldwide to expand the clinical-trials section of the prescribing information; in addition, further studies of patients with vascular dementia (in which cerebrovascular disease is the primary cause of their condition) are underway to support an application for a new indication.For full story and/or more product information: please visit www.janssen-cilag.com